Literature DB >> 33430922

Efficacy of a joint didactic intervention using the Junta De Andalucía School for Patients method to control prothrombin time in patients taking anticoagulants: protocol for a randomized controlled trial.

Leovigildo Ginel-Mendoza1, Alfonso Hidalgo-Natera2, Rocío Reina-Gonzalez2, Rafael Poyato-Ramos2, Juana Morales-Naranjo2, Inmaculada Lupiañez-Pérez2, Antonio Baca-Osorio2, Miguel Gutiérrez-Jansen2, María Paz Fernández-Lara2, Diego Lozano-Noriega2, Ulises Salgado-Carvallo2, Cristina Bandera-García2, Francisco Javier Navarro-Moya3.   

Abstract

BACKGROUND: Oral anticoagulant drugs represent an essential tool in the prevention of thromboembolic events. The ones in widespread use are vitamin K antagonists, whose plasma level is monitored by measuring prothrombin time using the international normalized ratio. If its values are out of the recommended range, the patient will have a higher risk of suffering from thromboembolic or hemorrhagic complications. Previous research has shown that approximately 33% of patients keep having values at an inappropriate level. The purpose of the proposed study is to improve the international normalized ratio control results by a joint didactic intervention based on the Junta de Andalucía School for Patients method that will be implemented by anticoagulated patients themselves.
METHODS: A randomized controlled trial will be undertaken at primary care centers from one healthcare area in Málaga (Andalusia, Spain). STUDY POPULATION: patients participating in an oral anticoagulant therapy program of vitamin K antagonists. First step: identification of patients in the oral anticoagulation therapy program with international normalized ratio control of the therapeutic level at 65% or less over total time. Second step: patients with international normalized ratio (INR) control figures under 2 or above 3 will be assigned to two different groups: Group 1 or joint intervention group: patients will be instructed in the joint didactic "from peer to peer," by a previously trained and expert anticoagulant patient. Group 2 or control group: the control group will receive the usual clinical practice. They will be evaluated by nurses about once a month, except for cases in which their INR figures are under 2 or above 3, and those patients will be evaluated more frequently. A total of 312 individuals will be required (156 in each group) to detect differences in INR figures equal to or higher than 15% between the groups. STUDY VARIABLES: time on therapeutic levels before and after the intervention; sociodemographic variables; vital signs; the existence of cardiovascular risk factors or accompanying diseases in the clinical records; laboratory test including complete blood counts, bleeding time, and prothrombin time or partial thromboplastin time; and blood chemistry, other prescribed drugs, and social support. A quasi-experimental analytic study with before-after statistical analysis of the intervention will be conducted. Linear regression models will be applied for the main variable results (international normalized ratio value, time on therapeutic level) inputting sociodemographic variables, accompanying diseases, and social support. TRIAL REGISTRATION: ClinicalTrials.gov NCT03647254 . Registered on 27 August 2018.

Entities:  

Keywords:  Anticoagulants, acenocoumarol, warfarin, health education; Conditions: health education, patient education as topic, and blood coagulation; Patient participation; Randomized control trial

Mesh:

Substances:

Year:  2021        PMID: 33430922      PMCID: PMC7798294          DOI: 10.1186/s13063-020-04972-1

Source DB:  PubMed          Journal:  Trials        ISSN: 1745-6215            Impact factor:   2.279


  22 in total

1.  Degree of Anticoagulation Control in Patients With Atrial Fibrillation in Spain: Need to Minimize Biases and Contextualize Results. Response by Cinza Sanjurjo et al.

Authors:  Sergio Cinza Sanjurjo; Daniel Rey Aldana; Enrique Gestal Pereira; Carlos Calvo Gómez
Journal:  Rev Esp Cardiol (Engl Ed)       Date:  2016-01-30

2.  Let the patient revolution begin.

Authors:  Tessa Richards; Victor M Montori; Fiona Godlee; Peter Lapsley; Dave Paul
Journal:  BMJ       Date:  2013-05-14

3.  Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients.

Authors:  A M Gallagher; E Setakis; J M Plumb; A Clemens; T-P van Staa
Journal:  Thromb Haemost       Date:  2011-09-08       Impact factor: 5.249

Review 4.  Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation.

Authors:  Danielle E Clarkesmith; Helen M Pattison; Phyo H Khaing; Deirdre A Lane
Journal:  Cochrane Database Syst Rev       Date:  2017-04-05

5.  Anticoagulation Control in Patients With Nonvalvular Atrial Fibrillation Attended at Primary Care Centers in Spain: The PAULA Study.

Authors:  Vivencio Barrios; Carlos Escobar; Luis Prieto; Genoveva Osorio; José Polo; José María Lobos; Diego Vargas; Nicolás García
Journal:  Rev Esp Cardiol (Engl Ed)       Date:  2015-07-11

6.  Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

Authors:  Robert G Hart; Lesly A Pearce; Maria I Aguilar
Journal:  Ann Intern Med       Date:  2007-06-19       Impact factor: 25.391

7.  Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting.

Authors:  Seol Young Han; Sebastian T Palmeri; Samuel H Broderick; Vic Hasselblad; Dave Rendall; Scott Stevens; Alan Tenaglia; Eric Velazquez; David Whellan; Galen Wagner; John F Heitner
Journal:  J Electrocardiol       Date:  2012-10-11       Impact factor: 1.438

8.  [Patients' characteristics and clinical management of atrial fibrillation in primary healthcare in Spain: FIATE Study].

Authors:  José María Lobos-Bejarano; José Carlos del Castillo-Rodríguez; Amparo Mena-González; José J Alemán-Sánchez; Antonio Cabrera de León; Gonzalo Barón-Esquivias; Agustín Pastor-Fuentes
Journal:  Med Clin (Barc)       Date:  2013-05-15       Impact factor: 1.725

Review 9.  Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review.

Authors:  Yi Wan; Carl Heneghan; Rafael Perera; Nia Roberts; Jennifer Hollowell; Paul Glasziou; Clare Bankhead; Yongyong Xu
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2008-11-05

10.  European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).

Authors:  Joep Perk; Guy De Backer; Helmut Gohlke; Ian Graham; Zeljko Reiner; W M Monique Verschuren; Christian Albus; Pascale Benlian; Gudrun Boysen; Renata Cifkova; Christi Deaton; Shah Ebrahim; Miles Fisher; Giuseppe Germano; Richard Hobbs; Arno Hoes; Sehnaz Karadeniz; Alessandro Mezzani; Eva Prescott; Lars Ryden; Martin Scherer; Mikko Syvänne; Wilma J M Scholte Op Reimer; Christiaan Vrints; David Wood; Jose Luis Zamorano; Faiez Zannad
Journal:  Int J Behav Med       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.